Peyronie's disease: An update of the medical management

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 4, 2004, Pages 799-805

  Maan, Zafar ^a,b   Arya, Manit ^a,c   Shergill, Iqbal ^a,d   Joseph, Jean V ^a   Patel, Hitendra R H ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b EPSOM AND ST HELIER UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^c ROYAL FREE HOSPITAL   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Erectile dysfunction; Intralesional therapy; Oral therapy; Peyronie's disease

Indexed keywords

4 AMINOBENZOATE POTASSIUM; ALPHA TOCOPHEROL; ALPHA2B INTERFERON; ANTIESTROGEN; COLCHICINE; COLLAGENASE; DEXAMETHASONE; IBUPROFEN; LEVACECARNINE; LIPOSOME; PLACEBO; PROCARBAZINE; STEROID; SUPEROXIDE DISMUTASE; TAMOXIFEN; TERFENADINE; VERAPAMIL;

ACUTE DISEASE; AGRANULOCYTOSIS; APLASTIC ANEMIA; ATROPHY; BLOOD TOXICITY; CHRONIC DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DEFORMITY; DISEASE CLASSIFICATION; DRUG ACTIVITY; DRUG COST; DRUG ERUPTION; DRUG PENETRATION; ENCAPSULATION; ERECTILE DYSFUNCTION; FIBROSIS; FLU LIKE SYNDROME; GASTROINTESTINAL TOXICITY; HOT FLUSH; HUMAN; IONTOPHORESIS; LASER; LIBIDO DISORDER; MALE; MYOPATHY; PAIN; PATHOPHYSIOLOGY; PEYRONIE DISEASE; REVIEW; SIDE EFFECT; SKIN BRUISING; SURGICAL TECHNIQUE; TREATMENT PLANNING; TUNICA ALBUGINEA; ULTRASOUND THERAPY;

EID: 1842843715     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.4.799     Document Type: Review

References (63)

1. GRIFF LC: Peyronie's disease. The role of radiation therapy and a general review. Am. J. Roentgenol. Radium. Ther. Nucl. Med. (1967) 100(4):916-919.
2. MCROBERTS JW: Peyronie's Disease. Surg. Gynecol. Obstet. (1969) 129(6):1291-1294.
3. BILLIG R, BAKER R, IMMERGUT M, MAXTED W: Peyronie's disease. Urology (1975) 6(4):409-418.
4. KADIOGLU A, TEFEKLI A, EROL B: A retrospective review of 307 men with peyronie's disease. J. Urol. (2002) 168:1075-1079.
5. HAKIM LS: PeyrAnie's disease: an update - the role of diagnostics. Int. J. Impot. Res. (2002) 14:321-323.
6. LINDSAY M, SCHAIN D, GRAMBSCH P et al.: The incidence of Peyronie's disease in Rochester, Minnesota, 1950 through 1984. J. Urol. (1991) 146:1007-1009.
7. SOMMER F, SCHWARZER U, WASSMER G et al.: Epidemiology of Peyronie's disease. Int J. Impot. Res. (2002) 14(5):379-383.
8. RHODEN EL, TELOKEN C, TING HY et al.: Prevalence of Peyronie's disease in men over 50 years old from Southern Brazil. Int. J. Impot. Res. (2001) 13(5):291-293.
9. GHOLAMI SS, LUE TF: Peyronie's disease. Urol. Clin. North Am. (2001) 28(2):377-390.
10. SMITH BH: Subclinical Peyronie's disease. Am. J. Clin. Pathol. (1969) 52:385-390.
11. HELLSTROM WJ, EIVALACQUA TJ: Peyronie's disease: etiology, medical and surgical therapy. J. Androl. (2000) 21(3):347-354.
12. CHILTON CP, CASTLE WM, WESTWOOD CA et al.: Factors associated in the aetiology of Peyronie's disease. Br. J. Urol. (1982) 54:748-750.
13. DEVINE CJ, HORTON CE: Peyronie's disease. Clin. Plast. Surg. (1998) 15:405-409.
14. JAROW JP,ALOWE FC: Penile trauma: an etiological factor in Peyronie's disease and erectile dysfunction. J. Urol. (1997) 158:1388.
15. LEVINE LA, MERRICK PF, LEE RC: Intralesional verapamil injection for the treatment of Peyronie's disease. J. Urol. (1994) 151:1522-1524.
16. EL-SAKKA AI, SELPH CA, YEN TS et al.: The effect of surgical trauma on rat tunica albuginea. J. Urol. (1998) 159:1700-1707
17. LUE TF: PeyronAe's disease: an anatomically based hypothesis and beyond. Int J. Impot. Res. (2002) 14:411-413.
18. BORDER W, NOBLE N: Transforming growth factor in tissue fibrosis. N. Engl. J. Med (1994) 331:1286-1291.
19. EL-SAKKA AI, HASSAN MU, NUNES L et al.: Histological and ultrastructural alterations in an animal model of Peyronie's disease. Br. J. Urol. (1998) 81:445-452.
20. EL-SAKKA AI, HASSOBA H, PILLARISETTY RJ et al.: Peyronie's disease is associated with an increase in transforming growth factor β protein expression. J. Urol. (1997) 158(4):1391-1394.
21. NOSS MB, DAY NS, CHRIST GJ et al.: The genetics and immunology of Peyronie's disease. Int J. Impot. Res. (2000) 12(4):S127-S132.
22. RALPH DJ, MIRAKIAN R, PRYOR JP et al.: The immunological features of Peyronie's disease. J. Urol. (1996) 155:159-162.
23. YUDKIN JS: Peyronie's disease and its association with metoprolol. Lancet (1977) 2:1355.
24. BIVALACQUA TJ, PUROHIT SK, HELLSTROM WJ: Peyronie's disease: advances in basic science and Pathophysiology. Curr. Urol. Rep. (2000) 1(4):297-301.
25. CARSON CC: PeyNonie's disease: newer diagnostic studies and surgical alternatives. Curr. Opin. Urol. (1994) 4(3):180-185.
26. LYKES K, GOLD D, NEWTON R et al.: Peyronie's disease is associated with Paget's disease of the bone. J. Bone Min. Res. (1997) 12:929-934.
27. NYBERG LM Jr, BIAS WB, HOCHBERG MC et al.: Identification of an inherited form of Peyronie's disease with autosomal dominant inheritance and association with Dupuytren's contracture and histocompatability B7 cross-reacting antigens. J. Urol. (1982) 128:48-51
28. EL-SAKKA AI, LUE TF: Peyronie's disease. Curr. Opinion. Urol. (1998) 8:203-209.
29. PHELAN MJ, RIPLEY PL, LYNCH MP: Methotrexate associated Peyronie's disease in the treatment of rheumatoid arthiritis. Br. J. Rheumatol. (1992) 31:425-426.
30. PRYOR JP, RALPH DJ: Clinical presentations of Peyronie's disease. Int. J. Impot. Res. (2002) 14:414-417.
31. GELBARD MK, DOREY F, JAMES K: The natural history of Peyronie's disease. J. Urol. (1990) 144:1376-1380.
32. DEVITE CJ Jr, SOMERS KD, JORDAN SG et al.: Proposal: trauma as the cause of Peyronie's lesion. J. Urol. (1997) 157:285-290.
33. GHOLAMI SS, GONZALEZ-CADAVID NF, LIN C et al.: Peyronie's disease: A review. J. Urol. (2003) 169(4):1234-1241.
34. MORELAND RB, NEHRA A: Pathophysiology of Peyronie's disease. Int J. Impot. Res (2002) 14:406-410.
35. LOPEZ JA, JAROW JP: Penile vascular evaluation of men with Peyronie's disease. J. Urol. (1993) 149(1):53-55.
36. GASIOR BL, LEVINE FJ, HOWANNESIAN A, KRANE RJ, GOLDSTEIN I: Plaque-associated corporal veno-occlusive dysfunction in idiopathic Peyronie's disease. a pharmacocavernosometric and pharmacocavernosographic study. World J. Urol. (1990) 8:90-96.
37. ORD J, CRANSTON D: Urology update - common conditions. Int. J. STD AIDS (2002) 13(9):640-644
38. WESSON MB: Peyronie's disease (plasCic induration): cause and treatment. J. Urol. (1943) 49:350.
39. MYNDERSE LA, MONGA M: Oral therapy for Peyronie's disease. Int. J. Impot. Res. (2002) 14:340-344.
40. HASCHE-KLUNDER R: Treatment of Peyronie's disease using para-aminobenzoate (Potaba). Urologe A. (1978) 17:224-227.
41. CARSON C: Potassium para-aminobenzoate for the treatment of Peyronie's disease: Is it effective? Tech. Urol. (1997) 3:135-139.
42. BIAGIOTTI G, CAVALLINI G: Acetyl-L-carnitine versus tamoxifen in the oral therapy of Peyronie's disease: A preliminary report. Br J. Urol. Int. (2001) 88(1):63-67.
43. RALPH DJ, BROOKS MD, BOTTAZO GF et al.: The treatment of Peyronie's disease with tamoxifen. Br. J. Urol. (1992) 70:648-651.
44. LISCHER GH, NEHRA A: New advances in Peyronie's disease. Curr. Opinion Urol. (2001) 11(6):631-636.
45. TELOKEN C, RHODEN EL, GRAZZIOTIN TM et al.: Tamoxifen versus placebo in the treatment of Peyronie's disease. J. Urol. (1999) 162:2003-2005.
46. AKKUS E, CARRIER S, REHMAN J et al.: Is colchicines effective in Peyronie's disease? A pilot study. Urology (1994) 44:291-295.
47. BYSTROM J: Induration penis plasitca. Experience of treatment with procarbazine Natulan. Scand. J. Urol. Nephrol. (1976) 10(1):21-25.
48. SCHROEDER-PRINTZEN I, HAUCK EW, WEIDNER W: New aspects in Peyronie's disease - a mini review. Andrologia (1999) 31(Suppl. 1):31-35.
49. GELBARD MY, JAMES N, RIACH P et al.: Collagenase versus placebo in the treatment of Peyronie's disease: A double blind study. J. Urol. (1993) 149:56-58.
50. LACY GL, ADAMS DM, HELLSTROM WJG: Intralesional interferon-alpha-2b for the treatment of Peyronie's disease. Int. J. Impot. Res. (2002) 14:336-339.
51. DUNCAN MR, BERMAN B, NSEYO UO: Regulation of the proliferation and biosynthetic activities of cultured human Peyronie's disease fibroblasts by interferons alpha, beta, and gamma. Scand. J. Urol. Nephrol. (1991) 25:89-94.
52. AHUJA S, BIVALAQUA T, CASE J et al.: A pilot study demonstrating clinical benefit from intralesional interferon alpha 2b in the treatment of Peyronie's disease. J. Androl. (1999) 20:444-448.
53. JUDGE IS, WIDNIEWSKI ZS: Intralesional interferon in the treatment of Peyronie's disease: A pilot study. Br J. Urol. (1997) 79:40-42.
54. LEIINE LA, DESTRADA CR: Review: intralesional verapamil for the treatment of Peyronie's disease. Int. J. Impot. Res. (2002) 14:324-328.
55. LEVINE LA: Advances in the medical therapy of Peyronie's disease. Int. J. Impot. Res. (1998) 10:123-124.
56. REHMAN J, BENET A, MELMAN A: Use of intralesional verapamil to dissolve Peyronie's disease plaque: A long term single blind study. Urology (1998) 51:620-626.
57. MCCAHY PJ, TAYAL SC: Peyronie's disease. Int. J. STD AIDS (1997) 8:141-144.
58. HAUCK EW, WEIDNER W: Francois de la Peyronie and the disease named after him. Lancet (2001) 357:2049-2051.
59. NATALE S, ASHDOWN J, MCLARTY E et al.: An evaluation of a new treatment for Peyronie's disease using ESWL [abstract]. Br. J. Urol. Int. (1999) 83(Suppl. 4):A153:56.
60. HUSAIN J, LYNN NN, JONES DK et al.: Extracorporeal shock wave therapy in the management of Peyronie's disease: Initial experience. Br J. Urol. Int. (2000) 86(4):466-468.
61. MONTORSI F, SALONIA A, GUAZZONI G et al.: Transdermal electromotive multi-drug administration for Peyronie's disease: preliminary results. J. Androl. (2000) 21:85-90.
62. RIEDL CR, PLAS E, VORAUER K et al.: Pilot study on liposomal recombinant human superoxide dismutase for the treatment of Peyronie's disease. Eur. Urol. (2001) 40:343-349.
63. BIVALACQUA TJ, PURHIT S, SRESTHDATTA A et al.: Potential role of nuclear-kB in the induction of Peyronie's-like condition in the rat. J. Urol. (1999) 161:781A.